FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475146005> ?p ?o ?g. }

• W2475146005 endingPage "40" @default.
• W2475146005 startingPage "40" @default.
• W2475146005 abstract "Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity.To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease.Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites.Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout.Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form- physical functioning subscale score (SF-36), and the change in the Berg Balance Test.Ninety patients with Huntington disease (mean age, 53.7 years; 40 women [44.4%]) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was -2.5 units (95% CI, -3.7 to -1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, -0.3 to 2.3; P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia.Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.clinicaltrials.gov Identifier: NCT01795859." @default.
• W2475146005 created "2016-07-22" @default.
• W2475146005 creator A5000577229 @default.
• W2475146005 creator A5002451678 @default.
• W2475146005 creator A5007239122 @default.
• W2475146005 creator A5007721195 @default.
• W2475146005 creator A5009905748 @default.
• W2475146005 creator A5015721522 @default.
• W2475146005 creator A5016152516 @default.
• W2475146005 creator A5016927406 @default.
• W2475146005 creator A5019755853 @default.
• W2475146005 creator A5020601667 @default.
• W2475146005 creator A5020726985 @default.
• W2475146005 creator A5020908038 @default.
• W2475146005 creator A5020958666 @default.
• W2475146005 creator A5022265869 @default.
• W2475146005 creator A5023047953 @default.
• W2475146005 creator A5023195554 @default.
• W2475146005 creator A5024433352 @default.
• W2475146005 creator A5026705332 @default.
• W2475146005 creator A5027745248 @default.
• W2475146005 creator A5028453258 @default.
• W2475146005 creator A5029320452 @default.
• W2475146005 creator A5029715384 @default.
• W2475146005 creator A5029779627 @default.
• W2475146005 creator A5030747867 @default.
• W2475146005 creator A5031151665 @default.
• W2475146005 creator A5033613846 @default.
• W2475146005 creator A5036520032 @default.
• W2475146005 creator A5037261601 @default.
• W2475146005 creator A5038389802 @default.
• W2475146005 creator A5039903147 @default.
• W2475146005 creator A5040600751 @default.
• W2475146005 creator A5041754989 @default.
• W2475146005 creator A5041872891 @default.
• W2475146005 creator A5043032087 @default.
• W2475146005 creator A5044584196 @default.
• W2475146005 creator A5046909063 @default.
• W2475146005 creator A5047488319 @default.
• W2475146005 creator A5048054839 @default.
• W2475146005 creator A5048100687 @default.
• W2475146005 creator A5048318577 @default.
• W2475146005 creator A5049664725 @default.
• W2475146005 creator A5049885283 @default.
• W2475146005 creator A5050596057 @default.
• W2475146005 creator A5052366543 @default.
• W2475146005 creator A5054891890 @default.
• W2475146005 creator A5054911069 @default.
• W2475146005 creator A5055912702 @default.
• W2475146005 creator A5056828532 @default.
• W2475146005 creator A5057528113 @default.
• W2475146005 creator A5058335515 @default.
• W2475146005 creator A5058452414 @default.
• W2475146005 creator A5059928924 @default.
• W2475146005 creator A5060405461 @default.
• W2475146005 creator A5060933950 @default.
• W2475146005 creator A5061104656 @default.
• W2475146005 creator A5061865212 @default.
• W2475146005 creator A5063740745 @default.
• W2475146005 creator A5064135529 @default.
• W2475146005 creator A5064384515 @default.
• W2475146005 creator A5064818671 @default.
• W2475146005 creator A5065187679 @default.
• W2475146005 creator A5065681374 @default.
• W2475146005 creator A5067591596 @default.
• W2475146005 creator A5067840969 @default.
• W2475146005 creator A5068188374 @default.
• W2475146005 creator A5068360393 @default.
• W2475146005 creator A5068655451 @default.
• W2475146005 creator A5068952855 @default.
• W2475146005 creator A5069099950 @default.
• W2475146005 creator A5069239813 @default.
• W2475146005 creator A5069345448 @default.
• W2475146005 creator A5069609751 @default.
• W2475146005 creator A5069996084 @default.
• W2475146005 creator A5070705950 @default.
• W2475146005 creator A5071159281 @default.
• W2475146005 creator A5073318519 @default.
• W2475146005 creator A5073414679 @default.
• W2475146005 creator A5073573130 @default.
• W2475146005 creator A5076862436 @default.
• W2475146005 creator A5079382183 @default.
• W2475146005 creator A5079629658 @default.
• W2475146005 creator A5080323879 @default.
• W2475146005 creator A5080807386 @default.
• W2475146005 creator A5080973366 @default.
• W2475146005 creator A5082179442 @default.
• W2475146005 creator A5082724740 @default.
• W2475146005 creator A5084812709 @default.
• W2475146005 creator A5086550890 @default.
• W2475146005 creator A5086992600 @default.
• W2475146005 creator A5087604896 @default.
• W2475146005 creator A5087762989 @default.
• W2475146005 creator A5088238884 @default.
• W2475146005 creator A5089384391 @default.
• W2475146005 creator A5090065099 @default.
• W2475146005 creator A5090800338 @default.
• W2475146005 creator A5091712411 @default.

• next